Avadel Pharmaceuticals

NASDAQ: AVDL · Real-Time Price · USD
13.69
0.19 (1.41%)
At close: Aug 15, 2025, 3:59 PM
13.64
-0.33%
After-hours: Aug 15, 2025, 07:44 PM EDT

Avadel Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
52.51M 50.41M 50.02M 41.5M 27.18M 19.45M 7.01M 1.5M n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
5.58M 4.81M 6.16M 2.79M 1.52M 693K 117K 36K 588K 586K 401K 247K 259K 201K 197K 199K 218K
Gross Profit
46.93M 45.6M 43.87M 38.72M 25.66M 18.76M 6.9M 1.46M -588K -586K -401K -247K -259K -201K -197K -199K -218K
Operating Income
-3M -3.3M -327K -12.74M -26.04M -24.9M -35.11M -49.54M -28.3M -23.04M -16.96M -29.94M -28.63M -23.14M -25.66M -21.94M -14.81M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-4.84M -4.96M -2.54M -14.33M -27.25M -28.89M -36.19M -64.34M -31.36M -27.36M -20.08M -33.25M -30.75M -26.64M -27.1M -23.35M -16.05M
Net Income
-4.92M -5.04M -2.63M -13.82M -27.34M -28.79M -36.27M -64.43M -30.78M -27.45M -20.15M -63.44M -26.42M -22.3M -22M -19.58M -13.45M
Selling & General & Admin
45.58M 44.62M 40.39M 47.41M 48.62M 41.3M 39.16M 46.78M 24.47M 16.98M 14.1M 21.8M 21.64M 21.03M 21.28M 15.17M 11.01M
Research & Development
4.35M 4.27M 3.8M 4.05M 3.07M 2.36M 2.85M 4.22M 3.83M 6.24M 2.93M 4.54M 6.99M 2.11M 4.38M 6.76M 3.85M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a -247K n/a n/a 33K 51K n/a 88K 78K
Operating Expenses
49.94M 48.9M 44.2M 51.46M 51.69M 43.66M 42.01M 51M 28.3M 23.22M 17.03M 26.34M 28.63M 23.14M 25.66M 21.94M 14.86M
Interest Expense
-2.24M 2.7M 2.82M 2.72M 2.59M 2.35M 1.98M 2.29M 3.26M 3.25M 3.56M 3.51M 2.02M 4.15M 1.93M 1.93M 1.93M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
55.51M 53.71M 50.35M 54.24M 53.21M 44.35M 42.12M 51.04M 28.3M 23.22M 17.03M 26.34M 28.63M 23.14M 25.66M 21.94M 14.86M
Income Tax Expense
78K 80K 88K -509K 93K -100K 89K 90K -580K 85K 70K 30.19M -4.32M -4.34M -5.1M -3.77M -2.61M
Shares Outstanding (Basic)
96.6M 96.39M 96.3M 96.15M 91.69M 95.02M 89.38M 77.25M 63.89M 63.23M 60.2M 59.04M 58.72M 58.62M 57.9M 58.49M 58.44M
Shares Outstanding (Diluted)
96.6M 96.39M 96.3M 96.15M 91.69M 95.02M 89.38M 77.25M 63.89M 63.23M 60.2M 59.04M 58.82M 58.62M 58.59M 58.49M 58.44M
EPS (Basic)
-0.05 -0.05 -0.03 -0.14 -0.3 -0.3 -0.41 -0.83 -0.48 -0.43 -0.33 -1.07 -0.45 -0.38 -0.38 -0.33 -0.23
EPS (Diluted)
-0.05 -0.05 -0.03 -0.14 -0.3 -0.3 -0.41 -0.83 -0.48 -0.43 -0.33 -1.07 -0.45 -0.38 -0.38 -0.33 -0.23
EBITDA
-3M -1.59M 1.32M -11.18M -24.12M -26.53M -33.61M -61.45M -27.52M -23.52M -16.11M -29.5M -28.47M -22.29M -24.98M -21.22M -13.9M
EBIT
n/a -2.26M 283K -11.62M -24.66M -26.53M -34.21M -62.05M -28.11M -24.11M -16.51M -29.75M -28.73M -22.49M -25.17M -21.42M -14.12M
Depreciation & Amortization
n/a 668K 1.03M 437K 541K -18K 595K 601K 588K 586K 401K 247K 259K 201K 197K 199K 218K